Duopharma Biotech Berhad Statistics
Total Valuation
KLSE:DPHARMA has a market cap or net worth of MYR 990.80 million. The enterprise value is 1.18 billion.
Important Dates
The next estimated earnings date is Tuesday, February 23, 2027.
| Earnings Date | Feb 23, 2027 |
| Ex-Dividend Date | Sep 3, 2026 |
Share Statistics
KLSE:DPHARMA has 961.94 million shares outstanding. The number of shares has decreased by -0.01% in one year.
| Current Share Class | 961.94M |
| Shares Outstanding | 961.94M |
| Shares Change (YoY) | -0.01% |
| Shares Change (QoQ) | -0.05% |
| Owned by Insiders (%) | 0.30% |
| Owned by Institutions (%) | 66.52% |
| Float | 529.68M |
Valuation Ratios
The trailing PE ratio is 9.20 and the forward PE ratio is 9.18. KLSE:DPHARMA's PEG ratio is 0.79.
| PE Ratio | 9.20 |
| Forward PE | 9.18 |
| PS Ratio | 1.08 |
| PB Ratio | 1.24 |
| P/TBV Ratio | 1.29 |
| P/FCF Ratio | 12.59 |
| P/OCF Ratio | 9.78 |
| PEG Ratio | 0.79 |
Financial Ratio History Enterprise Valuation
The stock's EV/EBITDA ratio is 5.97, with an EV/FCF ratio of 14.99.
| EV / Earnings | 10.97 |
| EV / Sales | 1.29 |
| EV / EBITDA | 5.97 |
| EV / EBIT | 7.45 |
| EV / FCF | 14.99 |
Financial Position
The company has a current ratio of 3.67, with a Debt / Equity ratio of 0.46.
| Current Ratio | 3.67 |
| Quick Ratio | 2.06 |
| Debt / Equity | 0.46 |
| Debt / EBITDA | 1.87 |
| Debt / FCF | 4.71 |
| Interest Coverage | 7.06 |
Financial Efficiency
Return on equity (ROE) is 13.93% and return on invested capital (ROIC) is 12.31%.
| Return on Equity (ROE) | 13.93% |
| Return on Assets (ROA) | 7.61% |
| Return on Invested Capital (ROIC) | 12.31% |
| Return on Capital Employed (ROCE) | 13.57% |
| Weighted Average Cost of Capital (WACC) | 5.87% |
| Revenue Per Employee | 468,562 |
| Profits Per Employee | 54,988 |
| Employee Count | 1,957 |
| Asset Turnover | 0.65 |
| Inventory Turnover | 1.65 |
Taxes
In the past 12 months, KLSE:DPHARMA has paid 33.68 million in taxes.
| Income Tax | 33.68M |
| Effective Tax Rate | 23.84% |
Stock Price Statistics
The stock price has decreased by -18.25% in the last 52 weeks. The beta is 0.38, so KLSE:DPHARMA's price volatility has been lower than the market average.
| Beta (5Y) | 0.38 |
| 52-Week Price Change | -18.25% |
| 50-Day Moving Average | 1.13 |
| 200-Day Moving Average | 1.25 |
| Relative Strength Index (RSI) | 33.15 |
| Average Volume (20 Days) | 293,805 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KLSE:DPHARMA had revenue of MYR 916.98 million and earned 107.61 million in profits. Earnings per share was 0.11.
| Revenue | 916.98M |
| Gross Profit | 394.01M |
| Operating Income | 158.34M |
| Pretax Income | 141.30M |
| Net Income | 107.61M |
| EBITDA | 194.45M |
| EBIT | 158.34M |
| Earnings Per Share (EPS) | 0.11 |
Full Income Statement Balance Sheet
The company has 181.20 million in cash and 370.68 million in debt, with a net cash position of -189.48 million or -0.20 per share.
| Cash & Cash Equivalents | 181.20M |
| Total Debt | 370.68M |
| Net Cash | -189.48M |
| Net Cash Per Share | -0.20 |
| Equity (Book Value) | 801.14M |
| Book Value Per Share | 0.83 |
| Working Capital | 558.73M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was 101.29 million and capital expenditures -22.57 million, giving a free cash flow of 78.72 million.
| Operating Cash Flow | 101.29M |
| Capital Expenditures | -22.57M |
| Depreciation & Amortization | 36.11M |
| Net Borrowing | -123.90M |
| Free Cash Flow | 78.72M |
| FCF Per Share | 0.08 |
Full Cash Flow Statement Margins
Gross margin is 42.97%, with operating and profit margins of 17.27% and 11.74%.
| Gross Margin | 42.97% |
| Operating Margin | 17.27% |
| Pretax Margin | 15.41% |
| Profit Margin | 11.74% |
| EBITDA Margin | 21.21% |
| EBIT Margin | 17.27% |
| FCF Margin | 8.58% |
Dividends & Yields
This stock pays an annual dividend of 0.05, which amounts to a dividend yield of 4.42%.
| Dividend Per Share | 0.05 |
| Dividend Yield | 4.42% |
| Dividend Growth (YoY) | 30.00% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 40.67% |
| FCF Payout Ratio | 55.60% |
| Buyback Yield | 0.01% |
| Shareholder Yield | 4.42% |
| Earnings Yield | 10.87% |
| FCF Yield | 7.95% |
Dividend Details Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside | |
Analyst Forecast
The average price target for KLSE:DPHARMA is 1.67, which is 61.75% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 1.67 |
| Price Target Difference | 61.75% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 2.46% |
| EPS Growth Forecast (3Y) | 9.16% |
Stock Splits
The last stock split was on September 6, 2021. It was a forward split with a ratio of 1.3333333333.
| Last Split Date | Sep 6, 2021 |
| Split Type | Forward |
| Split Ratio | 1.3333333333 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 7 |